FerGene Inc. - Company Profile

BioCentury | Nov 19, 2020

Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

...we didn’t have at Clarus.” Nick Galakatos, Blackstone Life Sciences The same is true for FerGene Inc....

BioCentury | Jun 19, 2020

Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...Eckhardt is SVP and head of Leaps by Bayer. Dewpoint is developing biomolecular condensate-based therapeutics. FerGene Inc....
...interim basis. Eck was CMO of Immatics Biotechnologies GmbH. Robin Sawka, BioCentury Staff Novavax Inc. Ziopharm Oncology Inc. Dewpoint Therapeutics FerGene Inc. Adverum...

BioCentury | May 29, 2020

Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

...Ipsen CFO Aymeric Le Chatelier since the departure of David Meek at YE19 to lead FerGene Inc....

Items per page:

1 - 3 of 3

BioCentury | Nov 19, 2020

Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

...we didn’t have at Clarus.” Nick Galakatos, Blackstone Life Sciences The same is true for FerGene Inc....

BioCentury | Jun 19, 2020

Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

BioCentury | May 29, 2020

Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

...Ipsen CFO Aymeric Le Chatelier since the departure of David Meek at YE19 to lead FerGene Inc....

Items per page:

1 - 3 of 3

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

Products & Solutions

About Biocentury

Contact

Privacy & Legal